In this week’s episode, John Stanford breaks down the evolving story of President Trump’s aggressive tariff strategy—focusing on a potential 200% tariff on pharmaceuticals. From a historical look at Trump’s decades-long affinity for tariffs to the current Section 232 investigation into pharmaceutical imports, we explore what these actions could mean for national security, drug prices, and innovation. Could this policy lead to onshoring more drug manufacturing—or just higher prices for patients? And what exactly is “Liberation Day”? What are your thoughts on a 200% pharma tariff?
Is this a smart way to strengthen domestic manufacturing—or a policy that could backfire? 📱If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:
https://x.com/MakingMedPodhttps://www.instagram.com/makingmedicinepod/https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true Timestamps:
0:00 Welcome and Overview
0:33 Why Tariffs? A Trump Trade Philosophy
1:32 Trump’s History with Tariffs
2:32 The 2025 Tariff Timeline
3:59 Liberation Day and the Global Tariff Shock
4:53 August 1st Deadline and Market Reaction
5:27 Trump Floats 200% Pharmaceutical Tariff
6:03 Section 232 Investigation Explained
6:56 Incubate’s Response and Global Supply Chain Concerns
7:50 National Security, APIs, and the Commerce Department
8:56 Trump’s Endgame: Manufacturing Medicines at Home
9:44 What the Industry Should Expect
10:26 Why We’re Still in the Dark
10:50 Next Week’s Preview: The Press Pass Segment
